0001209191-21-054168.txt : 20210831
0001209191-21-054168.hdr.sgml : 20210831
20210831194932
ACCESSION NUMBER: 0001209191-21-054168
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210830
FILED AS OF DATE: 20210831
DATE AS OF CHANGE: 20210831
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORDAN MARK S
CENTRAL INDEX KEY: 0001208541
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12111
FILM NUMBER: 211228398
MAIL ADDRESS:
STREET 1: 7315 WISCONSIN AVENUE
STREET 2: SUITE #250 WEST
CITY: BETHESDA
STATE: MD
ZIP: 20814
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MEDNAX, INC.
CENTRAL INDEX KEY: 0000893949
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060]
IRS NUMBER: 263667538
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1301 CONCORD TERRACE
CITY: SUNRISE
STATE: FL
ZIP: 33323
BUSINESS PHONE: 9543840175
MAIL ADDRESS:
STREET 1: 1301 CONCORD TERRACE
CITY: SUNRISE
STATE: FL
ZIP: 33323
FORMER COMPANY:
FORMER CONFORMED NAME: PEDIATRIX MEDICAL GROUP INC
DATE OF NAME CHANGE: 19950801
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-30
0
0000893949
MEDNAX, INC.
MD
0001208541
ORDAN MARK S
1301 CONCORD TERRACE
SUNRISE
FL
33323
1
1
0
0
Chief Executive Officer
Common Stock
2021-08-30
4
M
0
95000
17.65
A
303425
D
Common Stock
2021-08-30
4
S
0
95000
35.09
D
208425
D
Employee Stock Option (right to buy)
17.65
2021-08-30
4
M
0
95000
17.65
D
2023-10-10
Common Stock
95000
455331
D
Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan").
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date.
/s/ Dominic J. Andreano, as Attorney-in-Fact
2021-08-31